Alnylam Pharmaceuticals, Inc. - Net Worth and Insider Trading

Alnylam Pharmaceuticals, Inc. Net Worth

The estimated net worth of Alnylam Pharmaceuticals, Inc. is at least $117,929 dollars as of 2024-03-28. Alnylam Pharmaceuticals, Inc. is the 10% Owner of Regulus Therapeutics Inc and owns about 40,806 shares of Regulus Therapeutics Inc (RGLS) stock worth over $117,929. Details can be seen in Alnylam Pharmaceuticals, Inc.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Alnylam Pharmaceuticals, Inc. has not made any transactions after 2016-02-23 and currently still holds the listed stock(s).

Transaction Summary of Alnylam Pharmaceuticals, Inc.

To

Alnylam Pharmaceuticals, Inc. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alnylam Pharmaceuticals, Inc. owns 1 companies in total, including Regulus Therapeutics Inc () .

Click here to see the complete history of Alnylam Pharmaceuticals, Inc.’s form 4 insider trades.

Insider Ownership Summary of Alnylam Pharmaceuticals, Inc.

Ticker Comapny Transaction Date Type of Owner
Regulus Therapeutics Inc 2016-02-23 10 percent owner

Alnylam Pharmaceuticals, Inc. Latest Holdings Summary

Alnylam Pharmaceuticals, Inc. currently owns a total of 1 stock. Alnylam Pharmaceuticals, Inc. owns 40,806 shares of Regulus Therapeutics Inc (RGLS) as of February 23, 2016, with a value of $117,929.

Latest Holdings of Alnylam Pharmaceuticals, Inc.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RGLS Regulus Therapeutics Inc 2016-02-23 40,806 2.89 117,929

Holding Weightings of Alnylam Pharmaceuticals, Inc.


Alnylam Pharmaceuticals, Inc. Form 4 Trading Tracker

According to the SEC Form 4 filings, Alnylam Pharmaceuticals, Inc. has made a total of 0 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years. The most-recent trade in Regulus Therapeutics Inc is the sale of 8,333 shares on February 23, 2016, which brought Alnylam Pharmaceuticals, Inc. around $7 Million.

Insider Trading History of Alnylam Pharmaceuticals, Inc.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alnylam Pharmaceuticals, Inc. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Alnylam Pharmaceuticals, Inc. Ownership Network

Ownership Network List of Alnylam Pharmaceuticals, Inc.

No Data

Ownership Network Relation of Alnylam Pharmaceuticals, Inc.


Alnylam Pharmaceuticals, Inc. Owned Company Details

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Alnylam Pharmaceuticals, Inc. is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Financial Officer Crispina Calsada , Sr. VP & General Counsel Christopher Ray Aker , and Chief Operating Officer Joseph P Hagan .

Regulus Therapeutics Inc () Insider Trades Summary

Over the past 18 months, Alnylam Pharmaceuticals, Inc. made no insider transaction in Regulus Therapeutics Inc (). Other recent insider transactions involving Regulus Therapeutics Inc () include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Christopher Ray Aker , and a net sale of 5,468 shares made by Crispina Calsada .

In summary, during the past 3 months, insiders sold 25,516 shares of Regulus Therapeutics Inc () in total and bought 0 shares, with a net sale of 25,516 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 25,516 shares.

Regulus Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Regulus Therapeutics Inc Insider Transactions

No Available Data

Alnylam Pharmaceuticals, Inc. Mailing Address

Above is the net worth, insider trading, and ownership report for Alnylam Pharmaceuticals, Inc.. You might contact Alnylam Pharmaceuticals, Inc. via mailing address: 675 West Kendall Street, Henri A. Termeer Square, Cambridge Ma 02142.

Discussions on Alnylam Pharmaceuticals, Inc.

No discussions yet.